Showing 25 to 30 of 30 results
Virta Health's 60% Revenue Surge Driven by Employer Demand for Cost-Effective Weight Loss Solutions
Virta Health, a digital diabetes and weight loss program, achieved 60% revenue growth in 2024, exceeding $100 million, due to increasing employer demand for cost-effective alternatives to expensive GLP-1 drugs; the company's nutrition-focused approach leads to an average 13% weight loss in a year, e...
Virta Health's 60% Revenue Surge Driven by Employer Demand for Cost-Effective Weight Loss Solutions
Virta Health, a digital diabetes and weight loss program, achieved 60% revenue growth in 2024, exceeding $100 million, due to increasing employer demand for cost-effective alternatives to expensive GLP-1 drugs; the company's nutrition-focused approach leads to an average 13% weight loss in a year, e...
Progress
40% Bias Score
Women's Health Market: Growth Potential Despite Funding Challenges
The $41.3 billion women's health market, projected to reach $66 billion by 2033, faces challenges from limited funding (receiving only 2% of total health VC investment) and restrictive regulations, despite advancements in biotech and telehealth; however, recent successful exits and increased interes...
Women's Health Market: Growth Potential Despite Funding Challenges
The $41.3 billion women's health market, projected to reach $66 billion by 2033, faces challenges from limited funding (receiving only 2% of total health VC investment) and restrictive regulations, despite advancements in biotech and telehealth; however, recent successful exits and increased interes...
Progress
32% Bias Score
Congress Faces Deadline to Prevent End of Expanded Telehealth Coverage
The Telehealth Modernization Act of 2024, if not passed by December 31, will end expanded telehealth coverage under Medicare and Medicaid, impacting millions and potentially increasing healthcare costs.
Congress Faces Deadline to Prevent End of Expanded Telehealth Coverage
The Telehealth Modernization Act of 2024, if not passed by December 31, will end expanded telehealth coverage under Medicare and Medicaid, impacting millions and potentially increasing healthcare costs.
Progress
52% Bias Score
Hims & Hers Donates \$1 Million to Trump Inauguration Fund
Hims & Hers Health donated \$1 million to President-elect Trump's inauguration fund, following similar donations from other tech companies; the company's interest likely stems from the potential impact of future healthcare policies on their business, especially regarding compounded semaglutide.
Hims & Hers Donates \$1 Million to Trump Inauguration Fund
Hims & Hers Health donated \$1 million to President-elect Trump's inauguration fund, following similar donations from other tech companies; the company's interest likely stems from the potential impact of future healthcare policies on their business, especially regarding compounded semaglutide.
Progress
36% Bias Score
Lawsuit Alleges Amazon One Medical Negligence Led to Patient Death
Suzanne Wong is suing Amazon One Medical for medical negligence after her husband, Philip Tong, died hours after a virtual consultation where his serious symptoms were allegedly downplayed; the lawsuit also names Alta Bates Summit Medical Center.
Lawsuit Alleges Amazon One Medical Negligence Led to Patient Death
Suzanne Wong is suing Amazon One Medical for medical negligence after her husband, Philip Tong, died hours after a virtual consultation where his serious symptoms were allegedly downplayed; the lawsuit also names Alta Bates Summit Medical Center.
Progress
60% Bias Score
HIMS Stock Rises Despite Volatility, Driven by Diverse Revenue Streams
Hims & Hers Health (HIMS) stock price rose from $23.50 in July to $32.50 currently, despite September's dip below $14; its compounded semaglutide injections, representing under 10% of revenue, contribute to volatility, while the company shows continued strength.
HIMS Stock Rises Despite Volatility, Driven by Diverse Revenue Streams
Hims & Hers Health (HIMS) stock price rose from $23.50 in July to $32.50 currently, despite September's dip below $14; its compounded semaglutide injections, representing under 10% of revenue, contribute to volatility, while the company shows continued strength.
Progress
40% Bias Score
Showing 25 to 30 of 30 results